Outlicensing Small Molecules
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
40
NCT03138083
OMO-1 in Solid Malignancies
Phase: Phase 1/2
Role: Lead Sponsor
Start: Aug 8, 2017
Completion: May 25, 2020
Loading map...